Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neuroplast
Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Neuroplast B.V.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.